OKYO Pharma annual r&d spending
2020
2021
2022
2023
2024
2025
2026
OKYO Pharma R&D Spending Growth & History (OKYO)
OKYO Pharma's r&d spending was $1.8M for fiscal 2026.
View full OKYO Pharma company overviewOKYO Pharma annual r&d spending history
| Fiscal year | Period ended | R&D spending | Change | Growth |
|---|---|---|---|---|
| 2026 | 2026-03-31 | $1.8M | −$445,200 | −19.75% |
| 2025 | 2025-03-31 | $2.3M | −$6.0M | −72.65% |
| 2024 | 2024-03-31 | $8.2M | $1.9M | +30.07% |
| 2023 | 2023-03-31 | $6.3M | $4.7M | +293.75% |
| 2022 | 2022-03-31 | $1.6M | $1.3M | +362.06% |
| 2021 | 2021-03-31 | $348,347 | −$169,751 | −32.76% |
| 2020 | 2020-03-31 | $518,098 | — | — |
OKYO Pharma r&d spending trends
Over the last five fiscal years, OKYO Pharma's r&d spending increased from $348,347 to $1.8M, a change of $1.5M.
About the metric
What research and development spending means
Research and development (R&D) spending covers the costs of creating and improving products, services, software, technologies, and processes. Higher R&D spending may support future innovation, but the amount alone does not show whether those investments will generate returns.
Calculation and source
SEC-reported R&D expense
TickerStat standardizes research and development expense reported in company SEC filings, including the software-specific US-GAAP R&D concept when it is the filer’s primary R&D expense line. It is historical company-reported spending, not an estimate or forecast. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review OKYO Pharma source filings ↗